共查询到20条相似文献,搜索用时 15 毫秒
1.
目的:评价超选择性冠状动脉内注射硝普钠对急性心肌梗死(AMI)患者急诊经皮冠状动脉介入(PCI)治疗中梗死相关动脉(IRA)无复流现象的作用。方法:选择AMI急诊PCI后再通的IRA存在无复流现象者43例。21例患者经血栓抽吸导管超选择性梗死相关冠状动脉内注射法,22例患者采用常规指引导管内注射方法。药物均采用硝普钠100μg,2 s内"弹丸式"快速注射完毕。10 min后复查冠状动脉造影,评定冠状动脉血流TIMI分级及校正TIMI帧数(cTFC)。结果:两组均可明显改善急诊PCI后的无再流现象,超选择组所有患者梗死相关血管IRA血流恢复TIMIⅢ级,cTFC帧数由用药前的(84±7)帧降至(26±6)帧,与常规组相比较差异有统计学意义(P0.01)。结论:超选择性IRA内快速注射硝普钠100μg能更有效地改善AMI急诊PCI中无再流现象。 相似文献
2.
Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. 总被引:6,自引:0,他引:6
Giampaolo Niccoli Gaetano Antonio Lanza Sidney Shaw Enrico Romagnoli Domenico Gioia Francesco Burzotta Carlo Trani Mario A Mazzari Rocco Mongiardo Maria De Vita Antonio G Rebuzzi Thomas F Lüscher Filippo Crea 《European heart journal》2006,27(15):1793-1798
AIMS: No-reflow after a primary percutaneous coronary intervention (PCI) is associated with a high incidence of left ventricular (LV) failure and a poor prognosis. Endothelin-1 (ET-1) is a potent endothelium-derived vasoconstrictor peptide and an important modulator of neutrophil function. Elevated systemic ET-1 levels have recently been reported to predict a poor prognosis in patients with acute myocardial infarction (AMI) treated by primary PCI. We aimed to investigate the relationship between systemic ET-1 plasma levels and no-reflow in a group of AMI patients treated by primary PCI. METHODS AND RESULTS: A group of 51 patients (age 59+/-9.9 years, 44 males) with a first AMI, undergoing successful primary or rescue PCI, were included in the study. Angiographic no-reflow was defined as coronary TIMI flow grade < or =2 or TIMI flow 3 with a final myocardial blush grade < or =2. Blood samples were obtained from all patients on admission for ET-1 levels measurement. No reflow was observed in 31 patients (61%). Variables associated with no-reflow at univariate analysis included culprit lesion of the left anterior coronary descending artery (LAD) (67 vs. 29%, P=0.006) and ET-1 plasma levels (3.95+/-0.7 vs. 3.3+/-0.8 pg/mL, P=0.004). At multivariable logistic regression analysis, ET-1 was the only significant predictor of no-reflow (P=0.03) together with LAD as the culprit vessel (P=0.04). CONCLUSION: ET-1 plasma levels predict angiographic no-reflow after successful primary or rescue PCI. These findings suggest that ET-1 antagonists might be beneficial in the management of no-reflow. 相似文献
3.
OBJECTIVE: This study aimed to evaluate the relationship between the occurrence of the angiographic no-reflow phenomenon in patients with acute myocardial infarction (AMI) and the preintervention plaque composition as assessed by virtual histology intravascular ultrasound (VH-IVUS). BACKGROUND: The angiographic no-reflow phenomenon is an adverse prognostic factor in patients with AMI. METHOD: We enrolled consecutive 50 patients with ST-elevation AMI was treated by primary stent implantation. All culprit lesions were imaged by VH-IVUS before stent implantation. The angiographic no-reflow phenomenon was defined as a decrease in final TIMI flow grade compared with TIMI flow grade before stent implantation. RESULTS: Eight of 50 patients developed angiographic no-reflow after stent implantation. Gray-scale intravascular ultrasound (IVUS) showed significantly larger external elastic membrane volume and plaque burden in the no-reflow group. VH-IVUS showed a trend toward larger percentage of fibro-fatty plaque volume in the no-reflow group than in the reflow group (23.1 +/- 3.5 vs. 17.0 +/- 1.1%, P = 0.05). The presence of "marble"-like image, mainly consisting of fibro-fatty and fibrous plaque (plaque volume of fibro-fatty + fibrous >80% and containing fibro-fatty plaque volume >10%) was associated with angiographic no-reflow (P = 0.02). Corrected TIMI frame counts of the cases with "marble"-like image were significantly larger than the cases without it (46.8 +/- 5.6 vs. 27.4 +/- 2.3, P = 0.01). CONCLUSION: The culprit lesions with large plaque burden, or with "marble"-like image by VH-IVUS, are associated with the angiographic no-reflow phenomenon in patients with AMI. 相似文献
4.
目的探讨冠状动脉内注射地尔硫卓治疗直接经皮冠状动脉介入术(PCI)无复流的疗效。方法对23例直接PCI无复流患者给予梗死相关冠脉(IRA)内推注地尔硫卓2-4mg,分别于推注地尔硫卓前及推注后5min,用校正的心肌梗死溶栓治疗临床实验(TIMI)帧数(Corrected TIMI FrameCount,CTFC)评价IRA血流情况。结果23例无复流患者于IRA内注入地尔硫卓后CTFC由(60.45±12.10)帧降至(30.03±8.20)帧(P〈0.001),其中17例(复流组)IRA血流恢复至TIMI3级,6例(无复流组)IRA血流未恢复,有效率73.91%。结论冠脉内注射地尔硫卓治疗直接PCI无复流能有效地恢复患者IRA血流,可作为治疗无复流的一种方法。 相似文献
5.
Ali A Youssef Chiung-Jen Wu Chi-Ling Hang Cheng-I Cheng Cheng-Hsu Yang Chien-Jen Chen Yen-Hsun Chen Han-Tan Chai Sarah Chua Kuo-Ho Yeh Hon-Kan Yip 《Circulation journal》2006,70(12):1538-1542
BACKGROUND: The present study tested the hypothesis that when administered in conjunction with a PercuSurge device for treatment of acute myocardial infarction (AMI), intracoronary (IC) administration of nitroprusside (NTP) is safe and superior to IC administration of NTP alone or nitroglycerin (NTG) for reversing slow-flow or no-reflow, both of which occur frequently during primary percutaneous coronary intervention (PCI). METHODS AND RESULTS: Sixty-two patients with ST-segment elevation AMI of <12 h duration undergoing primary PCI were enrolled. When the final Thrombolysis In Myocardial Infarction (TIMI) flow was normal (TIMI-3), NTG 200 microg was administered first, followed by (5 min later) NTP 100 microg via an intra-guiding catheter. When final TIMI flow was 相似文献
6.
急性心肌梗死急诊介入治疗无再流发生的独立预测因素及对长期预后的影响 总被引:18,自引:1,他引:18
目的探讨急性心肌梗死(AMI)患者接受急诊经皮冠状动脉介入治疗(PCI)术中发生无再流的相关因素,并评估无再流对于该类患者的长期预后意义。方法930例行急诊PCI的AMI患者依其是否发生无再流分为两组,分析无再流发生的危险因素及两组患者院内和长期随访中主要不良心脏事件(MACE)。结果930例患者中共82例发生无再流(8.8%)。与正常血流组相比,无再流组患者的入院血糖水平[(9.8±4.3)mmol/L比(8.5±3.5)mmol/L,P<0.01]、肌酸激酶同工酶(CK-MB)峰值[(369.4±167.8)U/L比(282.3±161.7)U/L,P<0.01]、PCI术前0级血流(69.5%比54.5%,P=0.009)发生率较高,AMI前心绞痛发生率较低(19.5%比48.1%,P<0.01)。Logistic回归分析显示入院血糖水平、缺乏AMI前心绞痛、PCI术前0级血流及严重心力衰竭是无再流发生的独立预测因素。无再流患者院内MACE(37.8%比11.3%,P<0.01)和院后(2.5±1.2)年随访MACE发生率(37.5%比17.4%,P<0.01)均显著高于正常血流患者,Kaplan-Meier生存分析提示无再流组患者心因性病死率明显高于正常血流组患者(29.9%比11.7%;logrank检验,P<0.001)。Cox回归分析显示无再流是AMI患者长期心因性病死率的独立预测因素(相对危险度3.83,95%可信区间1.71~5.57)。结论入院血糖水平、缺乏AMI前心绞痛、PCI术前0级血流及严重心力衰竭是无再流发生的独立预测因素。与正常血流组相比,无再流组患者院内及长期随访MACE发生率分别增高3.3和2.2倍。 相似文献
7.
Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. 总被引:3,自引:0,他引:3
Raymond I Huang Parul Patel Paul Walinsky David L Fischman J David Ogilby Mark Awar Craig Frankil Michael P Savage 《Catheterization and cardiovascular interventions》2006,68(5):671-676
OBJECTIVES: The goal of this study was to evaluate the safety and efficacy of nicardipine in reversing no-reflow during percutaneous coronary intervention (PCI). BACKGROUND: No-reflow is a common complication of PCI in patients with acute coronary syndromes or venous bypass graft disease. Although nicardipine has an attractive pharmacological profile and has been used clinically to treat no-reflow, there is a paucity of published data regarding its effectiveness in this setting. METHODS: We conducted a retrospective analysis of 72 consecutive patients who received intracoronary nicardipine to reverse no-reflow during coronary intervention. Qualitative TIMI flow grade and quantitative TIMI frame count methods were used to assess the efficacy of nicardipine. RESULTS: A mean of 460 +/- 360 mcg of intracoronary nicardipine was used. No-reflow was successfully reversed with complete restoration of TIMI 3 flow in 71 of 72 patients (98.6%). TIMI flow grade improved from 1.65 +/- 0.53 prior to nicardipine to 2.97 +/- 0.24 after treatment (P < 0.001). TIMI frame count decreased from 57 +/- 40 at the time of no-reflow to 15 +/- 12 after nicardipine administration (P < 0.001). Nicardipine therapy was well tolerated without adverse hemodynamic or chronotropic effects. CONCLUSIONS: In this largest series to date, intracoronary nicardipine was demonstrated to be a safe and highly effective pharmacological agent to reverse no-reflow during PCI. 相似文献
8.
目的评价冠状动脉靶病变远端经微导管注射和直接冠状动脉内注射硝普钠对经皮冠状动脉介入( percutaneous coronary intervention, PCI) 治疗中“无复流”的作用。方法选择PCI治疗中存在“无复流”现象的患者56例为研究对象,其中21例入选普通组,经指引导管冠状动脉内注射硝普钠200斗g;23例入选改良组,经微导管注射硝普钠至靶病变远端:12例为对照组,经微导管注射O.9%氯化钠溶液至靶病变远端。10min后复查冠状动脉造影。评定冠状动脉血流心肌梗死溶栓试验(thrombolysis in myocardial infarction, TIMI)分级及校正TIMI帧数(corrected tbrombolysis in myocardial infarction framecount, CTFC)。结果3组均可改善PCI治疗后的“无复流”现象。普通组12例靶血管血流恢复TIMI3级,CTFC帧数由用药前的(83.2±8.3)帧降至(38.1±7.5)帧;而改良组21例血流恢复TIMI3级,CTFC帧数从(85.6±6.9)帧降至(27.3±6.8)帧;对照组1例血流恢复TIMI3级,CTFC帧数从(84.3±7.4)帧降至(50.8±8.2)帧。改良组疗效明显优于普通组和对照组,差异有统计学意义(P(0.01)。结论PCI治疗中,冠状动脉靶病变远端经微导管注射和经指引导管冠状动脉内注射硝普钠均能改善“无复流”现象。经微导管注射硝普钠至靶病变远端比经指引导管注射能更有效地改善PCI治疗中“无复流”现象。 相似文献
9.
Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality 总被引:5,自引:0,他引:5
Brosh D Assali AR Mager A Porter A Hasdai D Teplitsky I Rechavia E Fuchs S Battler A Kornowski R 《The American journal of cardiology》2007,99(4):442-445
No-reflow is a frequent event during percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI), and it may affect cardiac prognosis. We evaluated the occurrence of no-reflow as a predictor of outcomes in patients who underwent PCI for AMI. We prospectively collected data from 599 consecutive patients who underwent stent-based PCI for ST-elevation AMI by identifying those with no-reflow (Thrombosis In Myocardial Infarction [TIMI] grade <3 flow at completion of the procedure) and analyzing their baseline characteristics and clinical outcomes. Patients with no-reflow (n = 40, 6.7%) were older (67 +/- 13 vs 60 +/- 13 years, p = 0.002) and had longer ischemic times (5.5 +/- 3.7 vs 4.4 +/- 3.0 hours, p = 0.04) with more TIMI grade 0/1 flow at presentation (90% vs 64%, p = 0.001). No-reflow occurred mostly (73%) after stenting and often required intra-aortic balloon pump counterpulsation (30% vs 4.3%, p <0.001). Peak creatine kinase level was higher in patients with no-reflow (2,700 +/- 1,900 vs 2,000 +/- 1,800, p = 0.03) and more often associated with moderate or severe left ventricular dysfunction (68% vs 45%, p = 0.006) and increased 6-month mortality (12.5% vs 4.3%, p = 0.04). By multivariate analysis, no-reflow was an independent predictor of long-term mortality (odds ratio 3.4, p = 0.02). In addition, renal failure (odds ratio 4.39, p = 0.0025) and preprocedure TIMI grade 0/1 flow (odds ratio 2.1, p = 0.003) were independent predictors of no-reflow. In conclusion, the association of no-reflow with longer ischemic time and worse initial TIMI flow may indicate the presence of highly organized thrombus burden with higher propensity for distal embolization. Regardless of its mechanism, no-reflow was an independent predictor of increased mortality. 相似文献
10.
Hong SN Ahn Y Hwang SH Yoon NS Lee SR Moon JY Kim KH Hong YJ Park HW Kim JH Jeong MH Cho JG Park JC Kang JC 《The American journal of cardiology》2007,100(4):631-634
The no-reflow phenomenon after primary percutaneous coronary intervention (PCI) is associated with larger infarct size, worse functional recovery, and higher incidence of complication after acute ST-elevation myocardial infarction (STEMI). The aim of this study was to assess the relation between preprocedural N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and angiographic no-reflow phenomenon. We measured preprocedural serum NT-pro-BNP level in 159 consecutive patients with acute STEMI (aged 63 +/- 12 years; 72% men) before PCI. Angiographic no-reflow after PCI was defined as Thrombolysis In Myocardial Infarction (TIMI) flow grade <3. Baseline characteristics, including time from chest pain onset, between the no-reflow (n = 67) and normal-reflow groups (n = 92) were similar. NT-pro-BNP was significantly higher in the no-reflow group than the normal reflow group (1,982 +/- 3,314 vs 415 +/- 632 pg/ml; p = 0.005). Also, high-sensitivity C-reactive protein, monocytes, and troponin-T were significantly higher in the no-reflow group than the normal-reflow group. In the no-reflow group, NT-pro-BNP was much higher in patients with TIMI flow grade 0 (n = 41; 2,290 +/- 3,495 pg/ml) than those with TIMI grade 1 or 2 (n = 26; 1,575 +/- 2,340 pg/ml), but without significant difference. The area under the receiver-operating characteristic curve for NT-pro-BNP was 0.78, and the optimal cut-off value identified using receiver-operating characteristic curve analysis was 500 pg/ml. At the standard cut-off value of >500 pg/ml, increased NT-pro-BNP showed a high probability of no-reflow phenomenon (odds ratio 4.42, 95% confidence interval 1.15 to 17.00, p = 0.028). In conclusion, preprocedural NT-pro-BNP may be a strong predictor of the development of no-reflow phenomenon after PCI in patients with acute STEMI. 相似文献
11.
Mauro Maioli Michela Gallopin Mario Leoncini Francesco Bellandi Anna Toso Roberto Piero Dabizzi 《Catheterization and cardiovascular interventions》2005,65(4):484-491
In patients with acute myocardial infarction (AMI), the off-hour presentation is one of the major determinants of door-to-balloon delay. Moreover, the nighttime presentation is associated with increased mortality after primary coronary intervention (PCI). The prompt starting of a therapy able to start recanalization of the infarct-related artery before intervention might improve the results of off-hour primary PCI. We compared the outcome of 212 consecutive patients with AMI undergoing either direct or facilitated PCI according to the hour of presentation. Patients arriving off-hours were pretreated with alteplase (20 mg) and abciximab and underwent facilitated PCI. Patients presenting on-hours underwent direct PCI. A basal Thrombolysis in Myocardial Infarction (TIMI) flow grade 3 was observed in 1.0% of patients undergoing direct PCI and in 44% of patients undergoing facilitated PCI (P = 0.001). More patients starting PCI with a TIMI 3 flow achieved a postinterventional fast TIMI frame count (72.0% vs. 38.8% direct PCI group vs. 34.9% facilitated PCI group with basal TIMI 0-2; P = 0.001) and a TIMI perfusion grade 3 (66.0% vs. 38.8% direct PCI group vs. 39.7% facilitated PCI group with basal TIMI 0-2; P = 0.004). Preinterventional TIMI flow grade 3 was associated with a higher gain in left ventricular ejection fraction at 1 month (10.9% +/- 6.4% vs. 7.0% +/- 9.6% direct PCI group vs. 6.1% +/- 6.0% facilitated PCI group with basal TIMI 0-2; P = 0.005). No significant difference was observed in major bleedings, although there was a trend toward a higher risk in the facilitated PCI group. Patients in the facilitated PCI group achieving a basal TIMI 3 flow showed improved myocardial reperfusion and better left ventricular function recovery. Bleeding complications associated with combination therapy remained an important concern. 相似文献
12.
Depletion of antioxidants is associated with no-reflow phenomenon in acute myocardial infarction 总被引:3,自引:0,他引:3
Matsumoto H Inoue N Takaoka H Hata K Shinke T Yoshikawa R Masai H Watanabe S Ozawa T Yokoyama M 《Clinical cardiology》2004,27(8):466-470
BACKGROUND: No-reflow phenomenon is observed in approximately one-third of patients after percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI), and is associated with poor functional and clinical outcomes. On the other hand, the formation of free radicals in vasculature exerts deleterious effects on coronary microcirculation. HYPOTHESIS: We hypothesized that redox state in coronary circulation may play a crucial role in no-reflow phenomenon in AMI. METHODS: Consecutive 26 patients with first AMI who underwent primary PCI < 24 h after onset were enrolled. Before PCI, blood samples were obtained from coronary sinus to measure plasma or serum antioxidative vitamins (vitamin C, vitamin E, and beta-carotene) and antioxidative enzymes (extracellular glutathione peroxidase [GPX], superoxide dismutase, and catalase). After PCI, the corrected Thrombolysis In Myocardial Infarction (TIMI) frame count (CTFC) was measured in the target vessel. Patients with TIMI < or = 2 flow despite an optimal PCI result were designated as no-reflow group (Group NR, n = 6) and the others as reflow group (Group R, n = 20). RESULTS: Levels of vitamin C, vitamin E, and GPX before PCI were significantly lower in Group NR than in Group R. The CTFC correlated inversely with levels of vitamin C, vitamin E, and GPX (p < 0.05). CONCLUSIONS: Depletion of antioxidants is associated with no-reflow phenomenon in AMI. These findings strongly suggest that the redox state in coronary circulation plays an important role in the pathogenesis of no-reflow phenomenon. 相似文献
13.
替罗非班对急性心肌梗死经皮冠状动脉介入治疗中无复流现象的影响 总被引:1,自引:0,他引:1
目的观察血小板糖蛋白GPⅡb/Ⅲa受体拮抗剂盐酸替罗非班对ST段抬高型急性心肌梗死(STEAMI)患者经皮冠状动脉介入治疗(PCI)中无复流现象的影响.方法选择2006年1月至2006年12月哈尔滨医科大学第一附属医院心内科急诊入院的STEAMI患者104例,急诊冠状动脉造影结束后,按就诊顺序随机分为盐酸替罗非班组和对照组,观察两组PCI术后TIMI血流情况,24 h和1周心电图ST段回落情况2、4 h及30 d复合心血管终点事件发生率及出血情况.结果替罗非班组PCI术后TIMI 3级血流发生率92.3%,TIMI 0~2级血流发生率7.7%;对照组TIMI 3级血流发生率80.7%,TIMI 0~2级血流发生率19.3%,两组比较差异有统计学意义(P<0.05).替罗非班组24 h和1周心电图ST段完全回落率较对照组大(P<0.05).两组住院期间主要复合终点心血管事件发生率无显著差异(P>0.05),但替罗非班组有下降趋势.两组均无严重出血事件发生.结论急性心肌梗死直接PCI中应用盐酸替罗非班,可以改善术后梗死相关动脉无复流现象. 相似文献
14.
Reperfusion arrhythmias are associated with epicardial reperfusion but may also be a sign of vascular reperfusion injury which can be seen as no-reflow phenomenon on coronary angiography and predicts in-hospital complications and recovery of left ventricular (LV) function. No-reflow phenomenon (thrombolysis in myocardial infarction [TIMI] 相似文献
15.
替罗非班在老年人急诊经皮冠状动脉介入治疗中预防无复流的临床观察 总被引:1,自引:0,他引:1
目的观察老年人急诊PCI术中冠状动脉内注射替罗非班对术后无复流的影响。方法选择急性心肌梗死行急诊PCI患者163例,随机分为替罗非班组(83例)和对照组(80例)。替罗非班组在导丝通过病变后经导管冠状动脉内注射替罗非班10μg/kg,之后予替罗非班0.15μg/(kg·min)持续静脉滴注24 h。对照组给予常规治疗。观察2组患者TIMI、心肌灌注分级(TMPG),入院后30 d LVEF和左心室舒张末内径,心血管事件及出血并发症。结果替罗非班组TIMI血流3级和TMPG 2~3级比例较对照组明显升高,TIMI血流0~2级和TMPG 0~1级比例较对照组明显降低,差异有统计学意义(P<0.05)。替罗非班组LVEF较对照组明显改善,主要心血管事件较对照组明显降低,差异有统计学意义(P<0.05)。结论急诊PCI术中冠状动脉内注射替罗非班减少无复流,改善心肌灌注和心功能,且不增加心血管事件和并发症。 相似文献
16.
Cevat Kirma Akin Izgi Cihan Dundar Ali Cevat Tanalp Vecih Oduncu Soe Moe Aung Kenan Sonmez Bulent Mutlu Nihal Ozdemir Vedat Erentug 《Circulation journal》2008,72(5):716-721
BACKGROUND: The aim of the study was to identify clinical factors, angiographic findings, and procedural features that predict no-reflow phenomenon (Thrombolysis In Myocardial Infarction (TIMI) flow grade < or =2) in patients with acute myocardial infarction (AMI) who undergo primary percutaneous coronary intervention (PCI). METHODS AND RESULTS: A series of 382 consecutive patients with AMI underwent primary PCI within 12 h of symptom onset. Patients with ischemic symptoms continuing for more than 12 h were also included. Clinical, angiographic and procedural data were collected for each subject. Ninety-three (24.3%) of the patients developed no-reflow phenomenon, and their findings were compared with those of the reflow group. Univariate analysis showed that advanced age (>60 years), delayed reperfusion (> or =4 h), low (< or =1) TIMI flow prior to PCI, cut-off type total occlusion, high thrombus burden on baseline angiography, long target lesion (>13.5 mm) and large vessel diameter all correlated with no-reflow (p<0.05 for all). Multiple logistic regression analysis identified that advanced age (odds ratio (OR) 1.04, p=0.001), delayed reperfusion (OR 1.4, p=0.0004), low TIMI flow before primary PCI (OR 1.1, p=0.0002), target lesion length (OR 5.1, p=0.0003) and high thrombus burden (OR 1.6, p=0.03) on angiography as independent predictors of no-reflow phenomenon. CONCLUSION: The occurrence of no-reflow phenomenon after primary PCI can be predicted using simple clinical, angiographic and procedural features. In this selected group of patients, adjunctive pharmacotherapy and/or distal protection device may be of value. 相似文献
17.
急性心肌梗死再灌注心律失常不增加心肌损伤 总被引:1,自引:0,他引:1
目的探讨急性心肌梗死(AMI)患者PCI再灌注心律失常的临床意义。方法回顾性分析近年在我院接受直接PCI且成功开通梗死相关血管(IRA)的AMI患者228例。将其中开通IRA后数分钟内发生心肌缺血再灌注损伤(MIRI)的119例患者(MIRI组)分为3个亚组,即严重心动过缓和低血压(缓慢性心律失常组)、需电复律的严重室性心律失常(快速性心律失常组)和IRA前向血流≤TIMI2级且除外急性闭塞(无复流组)。结果(1)临床和造影资料:与无MIRI组相比,MIRI组缺血时间短,梗死前心绞痛所占比例低,多支血管病变、下壁梗死、右冠状动脉IRA、PCI前IRA血流TIM10级和肾功能不全所占比例高,住院病死率较高(13.4%比4.6%,P=0.021)。(2)血清心肌酶水平:缓慢性心律失常组肌酸激酶(OK)峰值中位数显著低于无MIRI组(20LOIU/L比2521IU/L,P=0.039),肌酸激酶同工酶(CK.MB)峰值中位数有低于无MIRI组的趋势(98IU/L比142IU/L,P=0.091);快速性心律失常组CK峰值中位数(2317IU/L)和CK-MB峰值中位数(134IU/L)与无MIRI组相比差异无统计学意义(P=0.627,0.500);无复流组CK峰值中位数(4573IU/L)和CK-MB峰值中位数(338IU/L)均显著高于无MIRI组(P均=0.000)。(3)超声心功能:无复流组左心室射血分数显著低于无MIRI组(38.7%±8.3%比51.2%±8.1%,P=0.000),左心室舒张末期容积显著大于快速性心律失常组[(135±32)ml比(105±19)ml,P=0.029],左心室收缩末期容积显著大于无MIRI组[(82±33)ml比(54±24)ml,P=0.008]和缓慢性心律失常组[(56±19)ml,P=0.025]。结论再灌注心律失常可能提示梗死区存活心肌多,而且不增加心肌损伤;无复流增加心肌损伤,导致永久的心功能障碍。 相似文献
18.
Effects of a distal protection device during primary stenting in patients with acute anterior myocardial infarction. 总被引:12,自引:0,他引:12
Tomohiro Nakamura Norifumi Kubo Yuichi Seki Nahoko Ikeda Takeshi Ishida Hiroshi Funayama Shigemasa Hashimoto Takanori Yasu Mikihisa Fujii Masanobu Kawakami Muneyasu Saito 《Circulation journal》2004,68(8):763-768
BACKGROUND: The angiographic no-reflow phenomenon is an adverse prognostic factor in patients with acute myocardial infarction (AMI). The aim of the present study was to evaluate the effects of an occlusive balloon type distal protection device (PercuSurge GuardWire: GW) during primary stenting in patients with anterior AMI. METHODS AND RESULTS: The GW group included 42 patients treated by primary stenting with GW protection and the control group included 30 patients treated by primary stenting after thrombectomy without distal protection. Left ventricular (LV) function was measured and compared by left ventriculography obtained soon after percutaneous coronary intervention (PCI) and 3 weeks after onset. The corrected TIMI frame count values were lower in the GW group than in the control group (27.5+/-2.3 vs 35.1 +/-2.5, p=0.030). The number of patients with myocardial blush grade 3 after PCI was higher in the GW group than in the control group (45.7 vs 20.0%, p=0.029). Peak concentration of creatine kinase myocardial fraction was lower in the GW group than in the control group (326.6+/-41.5 vs 454.9+/-46.2 mg/dl, p=0.043). GW patients showed greater improvement at 3 weeks after PCI in terms of LV ejection fraction (+4.6+/-1.2 vs -1.1+/-1.5, p=0.004), LV end-systolic volume index (+0.5+/-2.4 vs +9.0+/-2.7, p=0.023), and regional wall motion abnormalities (-2.03+/-0.14 vs -2.51+/-0.14, p=0.018). CONCLUSION: Primary stenting with GW protection can restore epicardial coronary flow and myocardial perfusion, and also preserve LV function in anterior AMI. 相似文献
19.
Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. 总被引:9,自引:0,他引:9
Sang Yup Lim Eun Hui Bae Myung Ho Jeong Dong Goo Kang Yeon Sang Lee Kye Hun Kim Sang Hyun Lee Kyung Ho Yoon Seo Na Hong Hyung Wook Park Young Joon Hong Ju Han Kim Weon Kim Young Keun Ahn Jeong Gwan Cho Jong Chun Park Jung Chaee Kang 《Circulation journal》2004,68(10):928-932
BACKGROUND: This study aimed to clarify the effect of intracoronary administration of combined adenosine and nicorandil on the no-reflow phenomenon. METHODS AND RESULTS: Fifty patients (67+/-10 years, 30 male) with acute myocardial infarction (AMI) who developed no-reflow phenomenon during primary percutaneous coronary intervention (PCI) between June 2001 and May 2003 comprised the study group, which was divided into 2 groups: group I [25 patients, 67+/-10 years, 13 male; adenosine (24 microg/ml) alone in addition to nitrate] and group II [25 patients, 66+/-9 years, 17 male; combined intracoronary administration of adenosine and nicorandil (2 mg/ml) in addition to nitrate]. In-hospital and 6-month major adverse cardiac events (MACE) after PCI were compared between the 2 groups. Risk factors of coronary disease, left ventricular ejection fraction and wall motion score were not significantly different between the 2 groups (p=NS). Time interval from the onset of chest pain to PCI, number of involved vessels, lesion type according to ACC/AHA classification and TIMI flow grade (TFG) were not significantly different in both groups (p=NS). Incidence of thrombosis or dissection after balloon angioplasty, diameter and length of stent, and use of Reopro during PCI were not significantly different. TFG after PCI (2.0+/-0.9 vs 2.6+/-0.6, p=0.024), DeltaTFG (1.5+/-1.1 vs 2.2+/-1.0, p=0.033) and difference in TIMI frame count (TFC) before and after PCI (DeltaTFC) were greater in group II than group I (45.2+/-24.5 vs 63.6+/-23.2, p=0.014). Myocardial blush score 3 was obtained more frequently in group II than group I (44% vs 76%, p=0.014). In-hospital death did not occur in any of group II, but 4 patients of group I died (p=0.043). Two cases of MACE developed in each group and heart failure occurred in 3 (12%) of group I and 1 (4%) of group II patients during the 6-month follow-up (p=NS). CONCLUSIONS: Intracoronary administration of adenosine combined with nicorandil may improve both the occurrence of no-reflow in patients during PCI for AMI and short-term clinical outcome, compared with adenosine alone. 相似文献
20.
Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. 总被引:12,自引:0,他引:12
Gerald S Werner Klaus Lang Helmuth Kuehnert Hans R Figulla 《Catheterization and cardiovascular interventions》2002,57(4):444-451
No-reflow is a frequent observation during direct PTCA for acute myocardial infarction (AMI) and associated with a poor clinical outcome. This study assesses the value of verapamil for reversal of no-reflow during PTCA for AMI. In a consecutive series of 212 direct or rescue PTCAs for AMI, a TIMI flow grade < 3 was observed in 23 patients (10.8%). Ten of these patients had received GP IIb/IIIa antagonists before PTCA. Seven patients with AMI and TIMI grade 3 flow served as controls. All lesions were treated by stents. In 18 patients with systolic blood pressure > 90 mm Hg, nitroglycerine (0.1 mg i.c.) was given. Verapamil (1 mg over 2 min) was given via an infusion catheter distal to the angioplasty site. Before and after nitroglycerine, after verapamil, and 15 min later coronary flow was assessed by the TIMI frame count method (TFC). Nitroglycerine had no effect on TFC. Verapamil reduced TFC from 56 +/- 9 frames to 24 +/- 4 (P < 0.001). In controls, TFC did not change significantly. The TIMI flow grade was restored to TIMI flow grade 3 in 65%. In two of seven right coronary and one of three circumflex arteries, intermittent AV block II occurred during verapamil injection, which disappeared after atropine. No-reflow after PTCA for AMI can be reversed by intracoronary verapamil. This supports the hypothesis that no-reflow is caused by acute microvascular dysfunction probably because of a disorder in calcium homeostasis or microvascular spasm. 相似文献